November 18, 2019: EicOsis Named Sacramento's Most Innovative BioPharma Company EicOsis won the 2019 Sacramento Region Innovation Award in the Medical & Health - Bio pharma category based on their technology to develop a first-in-class, non-opioid therapy for treatment of inflammatory and neuropathic pain in humans and companion animals.
October 29, 2019: EicOsis Announces SBIR Grant Award from NCI/NIH The National Institute of Health has awarded a Small Business Innovation Research (SBIR) grant from the National Cancer Institute to EicOsis, LLC to support preclinical testing of soluble epoxide inhibitors for treating neuropathic pain associated with chemotherapy drugs.
October 9, 2019: EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble epoxide hydrolase (sEH) enzyme, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate Phase 1 clinical trials for their drug candidate, EC5026 (BPN-19186), for the treatment of pain. EicOsis anticipates starting Phase 1 clinical trials in healthy volunteers before the end of this year.
January 8, 2016: Eicosis, LLC Receives $4 Million To Develop Novel Treatment For Diabetic Neuropathic Pain EicOsis, LLC was awarded a federal grant totaling over $4 million to advance compounds through Phase 1 clinical trials for diabetic neuropathic pain. The grant, “Development of an Oral Analgesic for Neuropathic Pain”, is funded through The National Institutes of Health (NIH) Blueprint for Neuroscience Research (Blueprint).
July 7, 2015: Key mechanism that causes neuropathic pain found A biological process called endoplasmic reticulum stress appears to play a key role in causing neuropathic pain, according to a new study. The discovery could eventually lead to new therapeutics for controlling chronic pain associated with trauma, diabetes, shingles, multiple sclerosis or other conditions that cause nerve damage.
November 14, 2012: UC Davis to test experimental drug for laminitis in horses (VIDEO) Veterinarians at the University of California, Davis, School of Veterinary Medicine have announced plans to conduct the first clinical trial of an experimental drug that has shown promise in treating horses stricken with laminitis, an excruciatingly painful and often life-threatening foot-related disease.
June 26, 2015: Discovery could help combat chronic pain in diabetics Researchers at the University of California, Davis, have discovered a class of natural compounds found within the body that may someday lead to pain relief for millions of diabetics and others suffering from chronic pain.
September 1, 2006: Pest Control Research Leads To Pain Control Discovery A newly discovered enzyme inhibitor, identified by researchers originally looking for biological pest controls, may lead to pain relief for sufferers of arthritis and other inflammatory diseases, say researchers at the University of California, Davis. The finding, hailed by a noted inflammatory disease expert "as the most important discovery in inflammation in more than a decade," may also reduce side effects associated with the painkiller, Vioxx.
The National Institute on Drug Abuse (NIDA) has awarded a grant to EicOsis LLC as part of the NIH initiative Helping to End Addiction Long-Term (HEAL Initiative) to support human clinical trials of a novel compound that has been found effective for the treatment of pain in preclinical animal studies.
